| 1 |
28259950 | Vinblastine differs from Taxol as it inhibits the malignant phenotypes of NSCLC cells by increasing the phosphorylation of Op18/stathmin. | 2017 Apr |
2 |
| 2 |
25944168 | Anti-STMN1 therapy improves sensitivity to antimicrotubule drugs in esophageal squamous cell carcinoma. | 2015 Sep |
2 |
| 3 |
26030092 | Stathmin potentiates vinflunine and inhibits Paclitaxel activity. | 2015 |
3 |
| 4 |
22407961 | The microtubule cytoskeleton is required for a G2 cell cycle delay in cancer cells lacking stathmin and p53. | 2012 May |
1 |
| 5 |
18588888 | Stathmin/Op18 is a novel mediator of vinblastine activity. | 2008 Jul 23 |
4 |
| 6 |
17272681 | Reversal of stathmin-mediated resistance to paclitaxel and vinblastine in human breast carcinoma cells. | 2007 May |
2 |
| 7 |
17663418 | Protumorigenic overexpression of stathmin/Op18 by gain-of-function mutation in p53 in human hepatocarcinogenesis. | 2007 Sep |
1 |
| 8 |
16940412 | Comparison of the activities of the truncated halichondrin B analog NSC 707389 (E7389) with those of the parent compound and a proposed binding site on tubulin. | 2006 Dec |
1 |
| 9 |
12460900 | Effect of stathmin on the sensitivity to antimicrotubule drugs in human breast cancer. | 2002 Dec 1 |
3 |
| 10 |
11181174 | Effects of stathmin inhibition on the mitotic spindle. | 2001 Mar |
1 |